
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
EMA publishes reflection paper on issues regarding the parenteral administration of coated nanomedicines.
The European Medicines Agency (EMA) has published a
The reflection paper is one in a series of four guidance documents discussing nanomedicines. EMA’s Committee for Medicinal Products for Human Use began developing guidance on the development of new nanomedicines and nanosimilars in 2011.
Source:






